269 results about "Renal fibrosis" patented technology

The present invention is directed to a method of inhibiting at least one of vascular leakage, inflammation and fibrosis in an animal by administering to the animal a vascular leakage inhibiting amount of a composition, wherein at a substantially higher amount the composition is effective in inhibiting angiogenesis, and wherein the anti-angiogenic activity of the composition is separate from the vascular leakage inhibiting activity of the composition. The animal experiencing at least one of vascular leakage, inflammation and fibrosis has a disease selected from the group consisting of diabetes, chronic inflammation, brain edema, arthritis, uvietis, macular edema, cancer, hyperglycemia, a kidney inflammatory disease, a disorder resulting in kidney fibrosis, a disorder of the kidney resulting in proteinuria, and combinations thereof. The composition capable of inhibiting at least one of vascular leakage, inflammation and fibrosis is selected from the group consisting of angiostatin, fragments of angiostatin, analogs or derivatives of angiostatin, kringle 5 of plasminogen, fragments of kringle 5 of plasminogen, analogs or derivatives of kringle 5 of plasminogen, pigment epithelium-derived factor, fragments of pigment epithelium-derived factor, analogs or derivatives of pigment epithelium-derived factor and combinations thereof.

The present invention is use of arctigenin in preparing medicine for preventing and treating chronic kidney failure and kidney fibrosis. The present invention also provides medicine composition with arctigenin as active component for preventing and treating chronic kidney failure and kidney fibrosis. When the medicine composition is applied in preventing and treating chronic kidney failure and kidney fibrosis, the injection has dosage of 30mg-1000 mg, preferably 30-500 mg, and the orally taken dosage is 50-2000 mg, preferably 50-800 mg.

In one aspect, the invention provides methods for treating, inhibiting, alleviating or preventing fibrosis in a mammalian subject suffering, or at risk of developing a disease or disorder caused or exacerbated by fibrosis and / or inflammation. In one embodiment, the invention provides methods of treating a subject suffering from renal fibrosis. In one embodiment, the invention provides methods of reducing proteinuria in a subject suffering from a renal disease or condition associated with proteinuria. The methods comprise the step of administering, to a subject in need thereof, an amount of a MASP-2 inhibitory agent effective to inhibit MASP-2-dependent complement activation.

Inflammatory disorders, including obliterative airway disease, renal fibrosis, diabetic nephropathy, and liver fibrosis are treated with immunosuppressive triptolide compounds, in particular triptolide compounds effective to inhibit TGF-β production in a patient afflicted with such a disorder.

The invention relates to the use of human fat-derived mesenchymal stem cells in the treatment of diseases in kidney and ocular fundus. The invention provides the use of the human fat-derived mesenchymal stem cells in cell preparation for treating diseases in kidney and / or ocular fundus, such as acute kidney injury, renal fibrosis, renal tubular epithelial cell damage, retinosis, diabetic retinopathy and retinal tear. The cell preparation can promote the repair of kidney structure and damaged eyeball pathologic structure with good effect.

The invention discloses a radix scutellariae total flavonoids aglycon extract, also a preparation method of radix scutellariae total flavonoids aglycon extract and functions of treating and resisting renal fibrosis. Content of total flavonoids aglycons in the radix scutellariae total flavonoids aglycon extract is 45-70%. The extract is mainly composed of scutellarein, wogonin, oroxylin A and other aglycons. The preparation method of the extract is as follows: crushing radix scutellariae roots, screening by a No. 1 screen; adding 1-5 times amount of water, uniformly stirring, keeping temperature for enzymolysis at 32-40 DEG C for 5-9 hours, baking under vacuum at 60 DEG C, adding 2-8 times amount of ethyl acetate, continuously extracting for 6-10 hours, depressurizing, recycling solvent, thus obtaining total flavonoids aglycon extract. The extract can obviously relieve renal fibrosis symptoms when irrigated into a mouse stomach with renal fibrosis caused by mercuric chloride moulding and when a group of mice having the extract is compared with group of mice without having the extract. Results suggest that the total flavonoids aglycon extract has a dose dependence in preventing renal fibrosis.

The present invention provides for a new plate-based high throughput screening of collagen synthesis wherein the collagen is left intact in the cells. The present invention also provides for collagen synthesis assay methods, methods of identifying candidate compounds which modulate collagen synthesis, and collagen synthesis assay compositions useful for modeling collagen depositions disorders, comprising idiopathic pulmonary fibrosis, liver fibrosis, renal fibrosis, heart fibrosis, rheumatoid arthritis, and atherosclerotic plaques.

This document provides methods and materials involved in assessing renal structural alterations (e.g., renal fibrosis, glomerular basement thickening, mesangial matrix expansion, swollen podocytes, and foot processes effacement) as well as methods and materials involved in assessing outcomes. For example, methods and materials for using the level of urinary CNP (e.g., a urinary to plasma CNP ratio) to determine whether or not a mammal is developing renal structural alterations (e.g., renal fibrosis, glomerular basement thickening, mesangial matrix expansion, swollen podocytes, and foot processes effacement) as well as methods and materials for using the level of urinary CNP levels to identify patients having an increased likelihood of experiencing a poor outcome are provided.

The invention belongs to the traditional medicine technical field, which relates to a traditional Chinese medicine composition for curing early and intermediate chronic renal failure. Under the guidance of a traditional Chinese medicine theory that 'interior accumulation is blood stasis' and 'chronic diseases transforming to collaterals is blood stasis', with the treatment principle of differentiation of symptoms and sighs, differentiation of channels, and based on the principle of strengthening body resistance and reducing turbidity, promoting blood circulation and removing blood stasis, the invention adopts traditional medicine such as lanceolata, epicedium, salvia miltiorrhizae, prepared rhubarb, perilla, peach kernel and the like, which are made into the compositions. Confirmed by clinical and animal experiments, the invention has the renal protecting functions of improving clinical symptoms of patients with early and intermediate chronic renal failure, reducing retention of metabolites of bodies, improving anemia, adjusting lipid and calcium-phosphorus metabolism, reducing the expression of fibrosis factors in nephridial tissues, preventing and treating glomerulosclerosis, lightening renal tubule damage and renal interstitial inflammatory cell infiltration and delaying renal fibrosis. The invention has the advantages of safety, efficiency and low cost, which is applied to the long-term medication for patients with early and intermediate chronic renal failure.

The invention discloses a compound having a structure represented by formula (I) and used for a discoidin domain receptor micro-molecule inhibitor, or its pharmaceutically acceptable salt or stereo isomer or prodrug molecule. The above compounds can effectively inhibit the activity of the discoidin domain receptor, and can be used for preparing drugs for preventing and treating inflammations, liver fibration, kidney fibration, lung fibration, skin scars or atherosclerosis.

The invention discloses a polypeptide hydrogel. The polypeptide hydrogel is prepared by mixing a self-assembled peptide (SAP) aqueous solution with exosomes (Exos). The present invention also discloses a preparation method and application of the polypeptide hydrogel. The polypeptide hydrogel provided by the invention can effectively slow down the release of the Exos and prolong the half-life of the Exos; and the released Exos have the activity similar to that of newly-separated Exos, and can effectively reduce HK2 cell injury caused by hypoxia and promote the recovery of vascular endothelial damage. The polypeptide hydrogel disclosed by the invention is capable of effectively reducing acute kidney injury and slowing down renal fibrosis by reducing kidney cell apoptosis and inflammatory factors, the expression amount of kidney injury marker protein-neutrophil gelatinase-related apolipoprotein (NGAL), and the synthesis and secretion of renal extracellular matrix (ECM), and has a good clinical application prospect.

The invention discloses a cycloalkane thiophthene derivative and pharmaceutically acceptable salts, metabolic products or prodrugs thereof. A compound can be used for treating diseases related with STAT3 (Signal Transducer and Activator of Transcription 3) activation, such as ovarian cancer, endometrial cancer, cervical cancer, breast cancer, colon cancer, pancreatic cancer, lung cancer, brain cancer, prostate cancer, kidney cancer, liver cancer, bladder cancer, oral cancer, sarcoma, prostate cancer, head and neck squamous cell carcinoma, neuroglioma, melanoma, lymphoma, leukemia, and renal fibrosis, pulmonary fibrosis, rheumatoid arthritis, hair growth, arthritis, psoriasis, lupus erythematosus, inflammatory lung diseases and inflammatory bowel diseases. (The formula is shown in the description.).

The invention relates to the technical field of animal models and concretely, relates to a method for building an animal model with PHF 14 gene knockout-based acute kidney injury and renal fibrosis after injury. The invention builds a model of renal fibrosis after kidney injury under the genetic background of PHF 14 gene knockout under adult conditions and provides essential conditions for researching a use of a PHF 14 gene in fibrotic diseases. Compared with the existing PHF 14 knockout model, the PHF 14 gene knockout provided by the invention does not cause embryonic lethal. A test on adult-stage tamoxifen induced knockout of PHF 14 proves that the PHF 14 gene knockout does not cause embryonic lethal. Compared with a group without knockout, the group subjected to knockout has no substantial pathology of lung, liver and kidney. The method prevents systemic disease state-caused interference on following-up acute kidney injury model making and realizes individual research on use of the gene defect in renal fibrosis pathogenesis.

The invention discloses a traditional Chinese medicine composition for improving renal functions and restraining renal fibrosis. Active pharmaceutical ingredients of the traditional Chinese medicine composition comprise, by weight, 10-15 parts of the root of red-rooted salvia, 10-60 parts of astragalus membranaceus, 10-30 parts of herba epimedii, 5-30 parts of sinensis and 3-30 parts of prepared rhubarb. Clinical researches show that 168 patients with chronic renal insufficiency are treated by the traditional Chinese medicine composition, a remarkable clinical effect is obtained, clinical symptoms are reduced, the clinical symptoms of some patients are basically eliminated, the renal functions of the patients can be remarkably improved, blood urea nitrogen (BUN) and creatinine (Scr) are obviously reduced, and total effective rate achieves 88.66%. Animal researches show that the traditional Chinese medicine composition can delay development of chronic renal failure, and the mechanism of the traditional Chinese medicine composition is relative to effects of effectively restraining precipitation of renal tissue collagen and secretion of TGF (transforming growth factor)-beta, accordingly restraining renal fibrosis, and the like. The traditional Chinese medicine composition is low in clinical application cost and excellent in curative effect, and is safe and reliable.

The invention belongs to the technical field of a biological preparation, and discloses a novel biological preparation for resisting renal fibrosis, of human umbilical cord MSC exosome and a preparation method. The novel biological preparation for resisting renal fibrosis, of human umbilical cord MSC exosome has main component of cup-shaped membrane-shaped vesicles which are prepared through combination of intracellular multivesicular bodies with cell membranes, are secreted outside cells and are about 100nm in size. The preparation method of the novel biological preparation for resisting renal fibrosis, of human umbilical cord MSC exosome comprises an ultracentrifugation method, a chemical reagent precipitation method, an ultrafiltration and centrifugation method and a magnetic bead immunization method. When the MSC cell exosome is extracted and used for treatment of an animal model suffering from diabetic nephropathy, the inventor finds that MSC-Ex has the treatment effects of restraining YAP activity, allevaiting renal interstitial fibrosis and delaying diabetic nephropathy.

The invention relates to application of jaceosidin in preparation of drugs used for treating or preventing chronic kidney injury, specifically to application of jaceosidin in preparation of drugs used for treating or preventing chronic renal failure, renal fibrosis and diabetic nephropathy. In the above-mentioned application, the dosage range of applied jaceosidin is 10 to 500 mg, preferably, 10 to 250 mg. Jaceosidin exists in the form of a tablet, a pill, a granule, a capsule, syrup or the like, preferably, the tablet.

The invention relates to a novel-structure dopamine tripolymer aspongopus amide A extracted from insect Chinese medicine aspongopus capable of warming the middle-jiao and invigorating yang, a pharmaceutical composition containing the aspongopus amide A, and application thereof in preparing medicines and health food for treating diabetic nephropathy or chronic nephropathy. The clinical application of insect collateral-dredging theory proves that collaterals are related to pathological changes of blood capillaries. The aspongopus amide A has the functions of obviously inhibiting high-saccharide induced kidney mesenteric cell secretory cell epimatrix and inflammatory factor, and is a Smad3 phosphorylation inhibitor capable of obviously inhibiting TGF-beta1-induced Smad3 phosphorylation and Smad3 expression. The signal route of the TGF-beta / Smad3 is the main pathology of mediated organ fibrosis, which indicates that the compound has application value in chronic nephropathy, including diabetic nephropathy, renal fibrosis and the like.

The invention relates to wogonin and derivatives thereof, a prodrug of wogonin as well as medical use of wogonin and biologically-physiologically acceptable salts of wogonin and derivatives thereof for treating a chronic kidney disease, particularly for treating renal fibrosis and renal fibrosis-induced diseases.

<heading lvl="1">SUMMARY OF THE INVENTION < / heading> The use of gene therapy for the treatment of different kinds of fibrosis in human beings is disclosed. The purpose is the use of "therapeutic2 genes specifically directed to target organs to revert and / or prevent the development of the fibrosis process. The potential application of gene therapy to patients with fibrosis and / or cirrhosis will depend to a large extent on the successful delivery of genes which encode for therapeutic proteins to livers with severe fibrosis and that these genes which encode for proteins human MMP-8 active and latent, MMP-1, MMP-2, MMP-9 and MMP-13; human uPA wild type and / or modified (or its truncated version), the truncated receptor for TGF-beta type II and Smad-7 can be directed by adenovirus and / or other recombinant vectors that cannot transduce (infect) others organs. The recombinant adenoviruses (AdR) are vectors highly efficient for the transduction of therapeutic genes to diverse target cells. We have proved that they can carry genes to cirrhotic livers. The delivery of therapeutic genes through such adenoviral vectors and other recombinant vectors could also be performed using cationic and anionic liposomes (DOTMA). Therefore, we propose the use of this patent to be applied in the same manner to: Renal fibrosis Pulmonary fibrosis Hypertrophic and keloid scars (skin fibrosis), and Other kinds of fibrosis.

The invention belongs to the field of extraction of traditional Chinese medicine, and particularly relates to a cortex eucommiae extract composition for treating renal fibrosis and application of thecortex eucommiae extract composition. The cortex eucommiae extract composition is prepared from the components of aucubin, a mixed extract of geniposide and geniposidic acid, quercetin and chlorogenicacid through the steps of extraction, separation, purification and the like, and the cortex eucommiae extract composition can be further prepared into a preparation. A preparation method is simple and efficient, and the prepared cortex eucommiae extract composition has the good effect of treating renal fibrosis.

The present invention is directed to a method of using compounds of Formula (I) to inhibit Cathepsin B. Specifically the compounds of the present invention are useful as therapeutic agents for the treatment of tumor invasion, metastasis, Alzheimer's Disease, arthritis, inflammatory diseases such as chronic and acute pancreatitis, inflammatory airway disease, and bone and joint disorders, including osteoporosis, osteoarthritis, rheumatoid arthritis, psoriasis, and other autoimmune disorders, liver fibrosis, including liver fibrosis associated with HCV, all types of steatosis (including non-alcoholic steatohepatitis) and alcohol-associated steatohepatitis, non-alcoholic fatty liver disease, forms of pulmonary fibrosis including idiopathic pulmonary fibrosis, pathological diagnosis of interstitial pneumonia following lung biopsy, renal fibrosis, cardiac fibrosis, retinal angiogenesis and fibrosis / gliosis in the eye, schleroderma, and systemic sclerosis. The compounds of Formula (I) are also useful for treating subjects with both HCV and fibrosis in a mammal, particularly liver fibrosis, and subjects affirmatively diagnosed or at risk for both HCV and liver fibrosis.

The invention relates to compositions comprising vasoactive intestinal peptide (VIP) or fragments thereof, and the use of such compositions in the treatment of kidney disease, in particular kidney fibrosis, and other associated conditions.

The invention discloses a post-renal transplantation treating and health care traditional Chinese medicine. The post-renal transplantation treating and health care traditional Chinese medicine comprises active components and auxiliary materials. The active components comprise, by weight, 10-18 parts of turmeric, 15-30 parts of glossy privet fruits, 6-10 parts of bighead atractylodes rhizome, 10-15 parts of oriental wormwood, 8-12 parts of radix lsatidis, 10-15 parts of lysimachia christinae hance, 10-15 parts of polygonum cuspidatum, 5-10 parts of schisandra chinensis and 10-15 parts of Chinese dates. The post-renal transplantation treating and health care traditional Chinese medicine has the effects of detoxification, dampness resolving, kidney strengthening, liver protection, spleen tonifying, blood nourishing, blood circulation invigorating, diureses and heart strengthening; the physiological function of the kidney can be effectively strengthened; and drug-induced liver cirrhosis and renal fibrosis are prevented. Obvious treatment and prevention effects on edema, hydronephrosis, the fatty liver and the like are achieved. The post-renal transplantation treating and health care traditional Chinese medicine is used for post-renal transplantation, the rejection resisting capacity of the transplant kidney can be improved; and toxic and side effects of immunosuppressant on the liver and the kidney are reduced. The chronic allograft nephropathy can be prevented, and the comprehensive health care effect is achieved.

The invention belongs to the field of Chinese medicines, and relates to a Chinese medicinal compound preparation for preventing and controlling chronic kidney disease and renal fibrosis and a preparation method thereof. On the basis of the theory of 'body resistance weakened while pathogenic factors prevailing, insufficiency of Qi and blood, and blood stasis and collaterals obstruction' in traditional Chinese medical science, the Chinese medicinal compound preparation is prepared from Chinese medicines such as Danshen root, angelica sinensis, peach kernel, twotooth achyranthes root and processed rhubarb. Through animal experiment and clinical trial, the Chinese medicinal compound preparation can improve renal haemodynamics, adjust lipid metabolic disturbance, enhance oxidation resistance, and inhibit over expression of cell factors so as to improve glomerulosclerosis and interstitial fibrosis degree, protect residual renal structures and functions, and delay the process of early-stage and medium-stage chronic renal failure deterioration. The Chinese medicinal compound preparation is particularly suitable for treating patients who suffer from chronic kidney disease (CKD2-4) and renal fibrosis which comprise renal insufficiency, proteinuria, atrophy of kidney and the like.

To find a compound having a tissue fibrinosis-inhibitory activity and a fibrinolytic activity, and to provide a novel compound that is useful for preventing and / or treating tissue fibrinosis diseases (pulmonary fibrosis, renal fibrosis etc.), diseases caused by pathological blood clots such as ischemic heart diseases (myocardial infarction, angina), intraatrial thrombus, pulmonary embolism, deep venous thrombosis, disseminated intravascular coagulation, ischemic cerebral diseases (cerebral infarction, cerebral bleeding) and arteriosclerosis and the like. To provide a pharmaceutical drug comprising a 5-phenyl-3-pyridazinone derivative represented by the following general formula (I):and an optical isomer thereof, or a pharmaceutically acceptable salt thereof, or a hydrate or solvate thereof, useful for preventing and / or treating disease conditions or symptoms mediated by plasminogen activator inhibitor-1.

The invention discloses a miRNA marker which is miRNA-576. The miRNA-576 can be used for judging renal fibrosis progress and severity degree. Inspection proves that the miRNA-576 can effectively distinguish a renal fibrosis sample from a non-renal-fibrosis sample. The miRNA-576 can be used for preparing a drug for inhibiting renal fibrosis on the basis. A novel diagnosis method is provided for clinically diagnosing renal fibrosis at molecular level, and a novel drug target is provided for renal fibrosis gene therapy.

This invention provides methods of inhibiting the onset or progression of a fibrotic disease (or pre-fibrotic pathology) in a mammal. The method involves administering oen or more peptides (e.g., class A amphipathic helical peptides, G* peptides, etc.) as described herein to a mammal in need thereof, in an amount effective to inhibit the onset and / or progression of the fibrotic disease (or pre-fibrotic condition) in the mammal. In certain embodiments the fibrotic disease is selected from the group consisting of retroperitoneal fibrosis (RPF), hepatic fibrosis and / or chirrhosis, renal fibrosis, and pancreatic fibrosis

The invention relates to application of patchouli alcohol in the preparation of drugs for prevention and treatment of renal injury and also provides a drug to antagonize renal fibrosis to prevent or / and treat hypertensive renal injury. The drug is mainly made from patchouli alcohol or patchouli oil, or with other drugs, as well as pharmaceutically acceptable accessories or accessory ingredients. The drug provided herein can inhibit renal fibrosis and retard renal injury by: inhibiting RAS (renin-angiotensin system), down-regulating TGF-beta 1 and PAI-1 levels, inhibiting the proliferation andactivation of MFB, reducing matrix protein synthesis and ECM (extracellular deposition) and improving pathogenic change in kidney tissue. Therefore, the patchouli alcohol based on renal fibrosis inhibition has excellent application prospect in the prevention or / and treatment renal injury, particularly in the development of drugs for hypertensive renal injury.

The invention relates to a beta-carboline compound and a synthetic method and application thereof, and belongs to the technical field of medicine. The structure of the compound is shown as the formula I (the formula I is shown in the specification). After an initial test, it is indicated that the in-vitro anti-renal-fibrosis activity of the compound is remarkable, the treatment effect on renal interstitial fibrosis caused by obstruction of the left ureter of a Balb / c mouse is good, the good potential medical value is achieved, and the beta-carboline compound and the synthetic method and application thereof can be used for preparing various kinds of anti-renal-fibrosis and anti-chronic-kidney-disease medicine.